Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved vemurafenib for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic melanoma whose tumors are BRAF V600 positive.
This is written in the approval document as:
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Citation
Vemurafenib Monotherapy, 2020, version number 5, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRAF p.V600E | Melanoma | Vemurafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Vemurafenib |